Sorrento Therapeutics Current Ratio 2010-2023 | SRNE
Sorrento Therapeutics current ratio from 2010 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Sorrento Therapeutics Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2023-06-30 |
$0.13B |
$0.27B |
0.50 |
| 2023-03-31 |
$0.10B |
$0.17B |
0.61 |
| 2022-12-31 |
$0.10B |
$0.33B |
0.29 |
| 2022-09-30 |
$0.18B |
$0.20B |
0.88 |
| 2022-06-30 |
$0.20B |
$0.15B |
1.35 |
| 2022-03-31 |
$0.33B |
$0.20B |
1.62 |
| 2021-12-31 |
$0.17B |
$0.14B |
1.24 |
| 2021-09-30 |
$0.20B |
$0.18B |
1.15 |
| 2021-06-30 |
$0.16B |
$0.18B |
0.86 |
| 2021-03-31 |
$0.27B |
$0.10B |
2.77 |
| 2020-12-31 |
$0.09B |
$0.10B |
0.89 |
| 2020-09-30 |
$0.11B |
$0.09B |
1.15 |
| 2020-06-30 |
$0.06B |
$0.09B |
0.60 |
| 2020-03-31 |
$0.05B |
$0.09B |
0.55 |
| 2019-12-31 |
$0.07B |
$0.12B |
0.59 |
| 2019-09-30 |
$0.07B |
$0.11B |
0.60 |
| 2019-06-30 |
$0.09B |
$0.11B |
0.84 |
| 2019-03-31 |
$0.12B |
$0.07B |
1.60 |
| 2018-12-31 |
$0.18B |
$0.06B |
2.91 |
| 2018-09-30 |
$0.15B |
$0.08B |
1.76 |
| 2018-06-30 |
$0.06B |
$0.04B |
1.39 |
| 2018-03-31 |
$0.04B |
$0.05B |
0.71 |
| 2017-12-31 |
$0.03B |
$0.08B |
0.38 |
| 2017-09-30 |
$0.05B |
$0.08B |
0.54 |
| 2017-06-30 |
$0.06B |
$0.08B |
0.76 |
| 2017-03-31 |
$0.04B |
$0.07B |
0.59 |
| 2016-12-31 |
$0.09B |
$0.08B |
1.18 |
| 2016-09-30 |
$0.07B |
$0.04B |
1.99 |
| 2016-06-30 |
$0.15B |
$0.06B |
2.40 |
| 2016-03-31 |
$0.07B |
$0.03B |
2.52 |
| 2015-12-31 |
$0.14B |
$0.03B |
4.57 |
| 2015-09-30 |
$0.13B |
$0.03B |
4.79 |
| 2015-06-30 |
$0.05B |
$0.01B |
5.19 |
| 2015-03-31 |
$0.06B |
$0.01B |
6.61 |
| 2014-12-31 |
$0.07B |
$0.01B |
7.73 |
| 2014-09-30 |
$0.05B |
$0.01B |
5.27 |
| 2014-06-30 |
$0.05B |
$0.01B |
7.44 |
| 2014-03-31 |
$0.03B |
$0.01B |
5.95 |
| 2013-12-31 |
$0.03B |
$0.01B |
5.96 |
| 2013-09-30 |
$0.01B |
$0.00B |
2.97 |
| 2013-06-30 |
$0.01B |
$0.00B |
3.99 |
| 2013-03-31 |
$0.01B |
$0.00B |
8.27 |
| 2012-12-31 |
$0.01B |
$0.00B |
8.99 |
| 2012-09-30 |
$0.01B |
$0.00B |
12.13 |
| 2012-06-30 |
$0.01B |
$0.00B |
18.59 |
| 2012-03-31 |
$0.00B |
$0.00B |
7.93 |
| 2011-12-31 |
$0.00B |
$0.00B |
9.90 |
| 2011-09-30 |
$0.00B |
$0.00B |
4.97 |
| 2011-06-30 |
$0.00B |
$0.00B |
7.08 |
| 2011-03-31 |
$0.01B |
$0.00B |
4.24 |
| 2010-12-31 |
$0.01B |
$0.00B |
9.19 |
| 2010-09-30 |
$0.00B |
$0.00B |
4.83 |
| 2010-06-30 |
$0.00B |
$0.00B |
9.69 |
| 2010-03-31 |
$0.00B |
$0.00B |
14.66 |
| 2009-12-31 |
$0.00B |
$0.00B |
9.79 |
| 2009-09-30 |
$0.00B |
$0.00B |
18.54 |
| 2009-06-30 |
$0.00B |
$0.00B |
7.69 |
| 2009-03-31 |
$0.00B |
$0.00B |
9.76 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.015B |
$0.063B |
|
Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and infectious disease. Sorrento Therapeutics, Inc. is based in San Diego, California.
|
